Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® Cream in Adults with Moderate Atopic Dermatitis
Incyte Announces FDA Approval of Jakafi XR Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology Annual Meeting
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody in Patients with Microsatellite Stable Colorectal Cancer
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology Annual Meeting
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology Annual Meeting
Finlay Minerals Ltd. engages German Mining Networks and renews engagement with Investing News Network
